Chemotherapy of experimental Echinococcus multilocularis in jirds.
A total of 50 jirds (Meriones unguiculatus) were infected by intraperitoneal implantation of 0.20 g metacestode tissue of Echinococcus multilocularis. The feed of 4 groups of 10 animals each was treated for 35 days with 500 ppm albendazole, flubendazole, mebendazole or praziquantel; 1 group of 10 jirds served as unmedicated controls. At autopsy 2 weeks after the end of medication, the transplants had increased in size and weight, reaching a total weight of 78.11 g in the control group, 21.60 g in the albendazole-treated group, 3.63 g in the flubendazole-treated group, 7.00 g in the mebendazole-treated group and 68.91 g in the praziquantel-treated group. The percentage in reduction of parasitic tissue weight as compared with control values was 72%, 95%, 91% and 12%, respectively. The calculated daily drug intake was approximately 48 mg/kg body weight. Drug-related side effects were not observed.
Vanparijs
O
O
Department of Parasitology, Janssen Pharmaceutica, Beerse, Belgium.
D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000923:Anticestodal Agents / Q000627:therapeutic use*; D000969:Antinematodal Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D004443:Echinococcosis / Q000188:drug therapy*; D005260:Female; D005849:Gerbillinae; D008463:Mebendazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D011223:Praziquantel / Q000627:therapeutic use*
D000923:Anticestodal Agents; D000969:Antinematodal Agents; D001562:Benzimidazoles; D011223:Praziquantel; D008463:Mebendazole; D015766:Albendazole; C018945:flubendazole